SCHEMBL6651864

SCHEMBL6651864

COc1ccccc1P(C1CCCCC1)C1CCCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
LMNA P02545 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 3/20 0.39
ABCB1 P08183 1/20 0.39
TSHR P16473 2/20 0.38
ALOX15 P16050 1/20 0.38
KMT2A Q03164 1/20 0.38
HTR2C P28335 1/20 0.38
NPC1 O15118 1/20 0.38
TP53 P04637 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29527648 1.00 SMN1; SMN2 (0.42) SMN1; SMN2CA12CA1CA2CA4
SCHEMBL16694568 0.98 CA1 (0.43) SMN1; SMN2CA12CA1CA2CA4
SCHEMBL29527801 0.98 CA1 (0.43) SMN1; SMN2CA12CA1CA2CA4
SCHEMBL30829086 0.96 CA1 (0.41) SMN1; SMN2CA12CA1CA2CA4
SCHEMBL17239656 0.94 SMN1; SMN2 (0.38) SMN1; SMN2CA12CA1CA2CA4
SCHEMBL28824636 0.94 SMN1; SMN2 (0.38) SMN1; SMN2CA12CA1CA2CA4
SCHEMBL17240343 0.92 CA12 (0.38) SMN1; SMN2CA12CA1CA2CA4
SCHEMBL1291696 0.87 SMN1; SMN2 (0.43) SMN1; SMN2LMNAHPGDTSHRKMT2A
SCHEMBL30821692 0.87 SMN1; SMN2 (0.43) SMN1; SMN2LMNAHPGDTSHRKMT2A
SCHEMBL30217868 0.86 ABCB1 (0.40) SMN1; SMN2LMNANPSR1ALDH1A1ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12213376-B2 Organic photoelectric conversion material SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2025-01-28 US disclosed
US-20220310939-A1 ORGANIC PHOTOELECTRIC CONVERSION MATERIAL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2022-09-29 US disclosed
EP-4024486-A1 ORGANIC PHOTOELECTRIC CONVERSION MATERIAL SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2022-07-06 EP disclosed
EP-2990113-B1 METHOD FOR PRODUCING CATALYST FOR CYCLIC CARBONATE SYNTHESIS MARUZEN PETROCHEM CO LTD (JP) 2020-03-25 EP disclosed
EP-2990112-B1 METHOD FOR MANUFACTURING CATALYST FOR SYNTHESIZING CYCLIC CARBONATE MARUZEN PETROCHEM CO LTD (JP) 2020-03-25 EP disclosed
US-10029241-B2 Method for producing catalyst for cyclic carbonate synthesis MARUZEN PETROCHEMICAL CO., LTD. (JP) 2018-07-24 US disclosed
US-10011621-B2 Method for producing silica gel-immobolized phosphonium salt catalysts MARUZEN PETROCHEMICAL CO., LTD. (JP) 2018-07-03 US disclosed
US-9834536-B2 Method for producing catalyst for cyclic carbonate synthesis NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2017-12-05 US disclosed
EP-2871198-B1 METHOD FOR PRODUCING AROMATIC COMPOUND SUMITOMO CHEMICAL CO (JP) 2017-06-14 EP disclosed
US-9453103-B2 Method for producing aromatic compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-09-27 US disclosed
EP-2583958-A1 Ligands for metals and improved metal-catalyzed processes based thereon Massachusetts Institute of Technology (MIT) (US) 2013-04-24 EP disclosed
US-7560582-B2 Ligands for metals and improved metal-catalyzed processes based thereon MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2009-07-14 US disclosed
US-20080033171-A1 Ligands for Metals and Improved Metal-Catalyzed Processes Based Thereon MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2008-02-07 US disclosed
US-7223879-B2 Ligands for metals and improved metal-catalyzed processes based thereon MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2007-05-29 US disclosed
EP-1199303-B1 Process for producing retinol and intermediate compounds for producing the same SUMITOMO CHEMICAL CO (JP) 2004-09-22 EP disclosed
US-6784321-B2 1-((2-ARYLSULFONYL)(3-METHYL)(5-OXY)PENT-3-ENE)-2,6,6-TRIMETHY LCYCLOHEX-1-ENE DERIVATIVES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-08-31 US disclosed
US-20040082814-A1 Process for producing retinol and intermediate compounds for producing the same SUMITOMO CHEMICAL COMPANY, LIMITED 2004-04-29 US disclosed
US-6660888-B2 A disulfone compound of given formula SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-12-09 US disclosed
US-20020058844-A1 Process for producing retinol and intermediate compounds for producing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-05-16 US disclosed
EP-1199303-A1 Process for producing retinol and intermediate compounds for producing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-04-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10029241-B2 Method for producing catalyst for cyclic carbonate synthesis CYCS, CA7, CA9 SMN1; SMN2 4667/4885CA12 5/4885CA1 15/4885
US-20040082814-A1 Process for producing retinol and intermediate compounds for producing the same ADH4, ADH1B, ADH7 SMN1; SMN2 2604/4885CA12 3476/4885CA1 3435/4885
US-20080033171-A1 Ligands for Metals and Improved Metal-Catalyzed Processes Based Thereon THEM6, SOD1, SLC30A6 SMN1; SMN2 4366/4885CA12 73/4885CA1 314/4885
US-20020058844-A1 Process for producing retinol and intermediate compounds for producing the same ADH4, ADH1B, ADH7 SMN1; SMN2 2604/4885CA12 3476/4885CA1 3435/4885
US-10011621-B2 Method for producing silica gel-immobolized phosphonium salt catalysts SIK2, SIK3, SIK1 SMN1; SMN2 4562/4885CA12 252/4885CA1 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.